Dyne Therapeutics (DYN) reported a Q3 net loss Tuesday of $0.96 per diluted share, narrowing from a loss of $0.99 a year earlier.

Analysts surveyed by Capital IQ expected a loss of $0.71.

The company did not report any revenue for the quarter.

As of Sept. 30 the company had cash, cash equivalents, and marketable securities of $723.7 million, which it said should be sufficient to fund operations until at least H2 of 2026.

Shares of Dyne Therapeutics were up nearly 5% in recent premarket activity.